KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to -$508.2 million.

  • Jazz Pharmaceuticals' Cash from Investing Activities fell 253.12% to -$327.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 524.58%. This contributed to the annual value of -$508.2 million for FY2024, which is 211.66% down from last year.
  • Jazz Pharmaceuticals' Cash from Investing Activities amounted to -$508.2 million in FY2024, which was down 211.66% from -$163.1 million recorded in FY2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Cash from Investing Activities peaked at -$163.1 million during FY2023, and registered a low of -$5.2 billion during FY2021.
  • For the 3-year period, Jazz Pharmaceuticals' Cash from Investing Activities averaged around -$372.5 million, with its median value being -$446.2 million (2022).
  • Per our database at Business Quant, Jazz Pharmaceuticals' Cash from Investing Activities tumbled by 548.85% in 2020 and then spiked by 91.44% in 2022.
  • Over the past 5 years, Jazz Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$1.0 billion in 2020, then plummeted by 417.25% to -$5.2 billion in 2021, then soared by 91.44% to -$446.2 million in 2022, then soared by 63.46% to -$163.1 million in 2023, then crashed by 211.66% to -$508.2 million in 2024.